Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation

Kolb, 1995, Graft-versusleukemia effect of donor lymphocyte transfusions in marrow grafted patients [European Group for Blood and MarrowTransplantationWorking PartyChronicLeukemia.], Blood, 86, 2041, 10.1182/blood.V86.5.2041.bloodjournal8652041 Horowitz, 1990, Graft-versusleukemia reactions after bone marrow transplantation, Blood, 75, 555, 10.1182/blood.V75.3.555.555 Mackinnon, 1995, Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marow transplantation: separation of graftversus- leukemia responses from graft-versus-host disease, Blood, 86, 1261, 10.1182/blood.V86.4.1261.bloodjournal8641261 Cavazzana-Calvo, 1990, Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin, Transplantation, 50, 1, 10.1097/00007890-199007000-00001 Datta, 1994, Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions, Bone Marrow Transplant, 14, 517 Mavroudis, 1996, Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation, Bone Marrow Transplant, 17, 793 Koh, 1999, Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis, Bone Marrow Transplant, 23, 1071, 10.1038/sj.bmt.1701749 van Dijk, 1999, Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graftversus- host disease, Br J Haematol, 107, 169, 10.1046/j.1365-2141.1999.01675.x Rencher, 1996, Eliminating graft-versus-host potential from T cell immunotherapeutic populations, Bone Marrow Transplant, 18, 415 Mavroudis, 1998, Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versusleukaemia reations, Br J Haematol, 101, 565, 10.1046/j.1365-2141.1998.00748.x Montagna, 1999, Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity, Blood, 93, 3550, 10.1182/blood.V93.10.3550.410k24_3550_3557 Cavazzana-Calvo, 1994, Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination, Blood, 83, 2888, 10.1182/blood.V83.1.288.288 Harris, 1999, Prevention of graftversus- host disease (GvHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor, Bone Marrow Transplant, 23, 137, 10.1038/sj.bmt.1701535 Thorpe, 1988, Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages, Cancer Res, 48, 6396 Schnell, 2000, Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin, Leukemia, 14, 129, 10.1038/sj.leu.2401626 Kronke, 1986, Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin, Cancer Res, 46, 3295 Maino, 1998, Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression, Cytometry, 34, 207, 10.1002/(SICI)1097-0320(19981015)34:5<207::AID-CYTO1>3.0.CO;2-J Johnson, 1999, Graft-vs.-host and graftvs.- leukemia reactions after delayed infusions of donor T-subsets, Biol Blood Marrow Transplant, 5, 123, 10.1053/bbmt.1999.v5.pm10392958 Fowler, 1994, Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice, Blood, 84, 3540, 10.1182/blood.V84.10.3540.3540 Fowler, 1998, CD8+ T cells of Tc2 phenotype mediated a GVL effect and prevent marrow rejection, Vox Sang, 74, 331, 10.1111/j.1423-0410.1998.tb05439.x Blazar, 1994, In vivo blockade of CD28/CTLA4:B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barriers in mice, Blood, 83, 3815, 10.1182/blood.V83.12.3815.3815 Tiberghien, 1994, Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?, Blood, 84, 1333, 10.1182/blood.V84.4.1333.1333 Bonini, 1997, HSV-TK gene transfer into donor lymphocytes for control of allogeneic graftversus- leukemia, Science, 276, 1719, 10.1126/science.276.5319.1719 Hansen, 2000, Use of recipientderived dendritic cells for identifying and removing alloreactive T cells from allografts, Blood, 96, 33a Goulmy, 1997, Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy, Immunol Rev, 157, 125, 10.1111/j.1600-065X.1997.tb00978.x Warren, 1998, Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation, Curr Opin Hematol, 5, 429, 10.1097/00062752-199811000-00013 Jiang, 1997, Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease, Bone Marrow Transplant, 19, 899, 10.1038/sj.bmt.1700769 Dolstra, 1997, Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL, J Immunol, 158, 560, 10.4049/jimmunol.158.2.560 Childs, 1999, Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses, Blood, 94, 3234, 10.1182/blood.V94.9.3234 Khouri, 1998, Transplant-lite: induction of graft-versus-malignancy using fludarabinebased nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies, J Clin Oncol, 16, 2817, 10.1200/JCO.1998.16.8.2817 Slavin, 1998, Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases, Blood, 91, 756, 10.1182/blood.V91.3.756